Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer
{{output}}
Introduction: Tucatinib, a small molecule HER2 inhibitor, was approved in inoperable or metastatic HER2 + breast cancer. As many patients have tumors in challenging surgical locations, there is a need for imaging metrics to chara... ...
